PatientsVille.com Logo

COAGULOPATHY and Tikosyn

PatientsVille

COAGULOPATHY Symptoms and Causes

Normally, if you get hurt, your body forms a blood clot to stop the bleeding. For blood to clot, your body needs cells called platelets and proteins known as clotting factors. If you have a bleeding disorder, you either do not have enough platelets or clotting factors or they don't work the way they should.

Bleeding disorders can be the result of other diseases, such as severe liver disease or a lack of vitamin K. They can also be inherited. Hemophilia is an inherited bleeding disorder. Bleeding disorders can also be a side effect of medicines such as blood thinners.

Various blood tests can check for a bleeding disorder. You will also have a physical exam and history. Treatments depend on the cause. They may include medicines and transfusions of blood, platelets, or clotting factor.

Check out the latest treatments for COAGULOPATHY

COAGULOPATHY treatment research studies

Tikosyn clinical trials, surveys and public health registries


Find Drug Side Effect reports



Tikosyn Side Effects

Atrial Fibrillation (267)
Dizziness (156)
Fatigue (116)
Dyspnoea (110)
Headache (94)
Electrocardiogram Qt Prolonged (86)
Heart Rate Increased (83)
Condition Aggravated (79)
Arrhythmia (74)
Asthenia (68)
Nausea (62)
Chest Pain (61)
Diarrhoea (52)
Palpitations (48)
Feeling Abnormal (48)
Torsade De Pointes (45)
Urinary Tract Infection (40)
Blood Pressure Increased (39)
Cardiac Disorder (35)
Insomnia (34)
Heart Rate Irregular (32)
Pneumonia (31)
Hypertension (31)
Death (30)
Blood Potassium Decreased (30)
Malaise (30)
Ventricular Tachycardia (30)
Pain In Extremity (28)
Weight Decreased (27)
Vision Blurred (26)
Arthralgia (25)
Heart Rate Decreased (25)
Cough (25)
Weight Increased (24)
Anxiety (23)
Nasopharyngitis (22)
Tremor (21)
Hyperhidrosis (21)
Blood Creatinine Increased (20)
Chest Discomfort (20)
Renal Impairment (20)
Fall (20)
Muscle Spasms (19)
Vomiting (19)
Infection (19)
Blood Pressure Decreased (19)
Bronchitis (18)
Cardiac Failure Congestive (18)
Depression (18)
Dysphagia (18)

➢ More


Common Meds

Abilify (10132)
Adderall (1304)
Amlodipine (6664)
Amoxicillin (4387)
Benadryl (1568)
Celebrex (12876 )
Celexa (1342)
Cialis (2975)
Cipro (8580)
Citalopram (7792)
Crestor (18839)
Cymbalta (14373)
Doxycycline (1757)
Effexor (7289)
Flexeril (435)
Flomax (2177)
Fluoxetine (4261)
Gabapentin (4593)
Hydrocodone (2469)
Ibuprofen (8222)
Lantus (10968)
Lexapro (3499)
Lipitor (17769)
Lisinopril (8919)
Lyrica (27148)
Medrol (650)
Mirena (41254)
Mobic (957)
Morphine (5356)
Naproxen (538)
Neurontin (6501)
Oxycodone (4438)
Pradaxa (13372)
Prednisone (5926)
Prilosec (2631)
Prozac (1954)
Seroquel (27216)
Simvastatin (8348)
Synthroid (4452)
Tamiflu (5585)
Topamax (3748)
Tramadol (5054)
Trazodone (1458)
Viagra (5394)
Vicodin (1153)
Wellbutrin (6324)
Xanax (2847)
Zocor (5718)
Zoloft(6792)
Zyrtec(1669)

COAGULOPATHY Clinical Trials and Studies

Treatments might be new drugs or new combinations of drugs, new surgical procedures or devices, or new ways to use existing treatments. The goal of clinical trials is to determine if a new test or treatment works and is safe. Clinical trials can also look at other aspects of care, such as improving the quality of life for people with chronic illnesses. People participate in clinical trials for a variety of reasons. Healthy volunteers say they participate to help others and to contribute to moving science forward. Participants with an illness or disease also participate to help others, but also to possibly receive the newest treatment and to have the additional care and attention from the clinical trial staff.
Rank Status Study
1 Recruiting Fibrinogen for Treatment of Pediatric Dilutional Coagulopathy. FibPaed Study.
Conditions: Blood Coagulation Disorders;   Hemorrhage
Intervention: Drug: Human fibrinogen concentrate
Outcome Measures: Total amount of transfused red cell concentrate;   coagulation measurements;   length of stay on PICU;   Additional transfusion/blood products requirements;   Occurence of re-bleeding, surgical revision;   Occurence of (severe) adverse events
2 Unknown  RETIC Trial: Reversal of Trauma Induced Coagulopathy Using Coagulation Factor Concentrates or Fresh Frozen Plasma
Condition: Major Trauma
Interventions: Drug: Fibrinogen concentrate, Prothrombin complex concentrate and FXIII concentrate;   Drug: Fresh Frozen Plasma blood type 0, A, B and AB
Outcome Measure: Multiple Organ Failure (MOF)
3 Recruiting Comparison of Rapid Thrombelastography and Conventional Coagulation Testing for Haemostatic Resuscitation in Trauma
Condition: Acute Coagulopathy
Interventions: Biological: Blood product transfusion based on conventional coagulation tests.;   Biological: Blood product transfusion based on rapid thrombelastography (r-TEG) results.
Outcome Measures: Change in r-TEG parameters [TEG-ACT, alpha angle, K value, MA (maximum amplitude), G value (clot strength), and fibrinolysis (EPL=estimated percent lysis)].;   Change in conventional coagulation test results [aPTT, INR, platelet count, fibrinogen level, D-dimer].;   Quality and quantity of blood products transfused.;   Hemorrhage-related deaths specified as very early mortality (<2 hours post-injury), early mortality (2<6 hours post-injury) and delayed mortality (6-24 hours post-injury): incidence, cause and hours since injury.;   Late mortality (>24 hours post-injury through day 30): incidence, cause and days since injury.;   Cessation of coagulopathic bleeding based upon clinical impressions of the treating surgeons and review of operative records and outcome (hours since injury).;   Timeframe of all transfusions during the first 24 hours post-injury (stratified by: 0<2 hours, 2<4 hours, 4<6 hours, 6<12 hours, and 12-24 hours post-injury).;   Number of participants with Multiple Organ Failure (MOF) during this hospitalization.;   Length of stay (days) in the surgical intensive care unit (SICU) and number of ventilator free days in the SICU.
4 Recruiting Effect of Antioxidant Vitamins on Coagulopathy and Nosocomial Pneumonia After Severe Trauma
Conditions: Coagulopathy;   Nosocomial Pneumonia
Interventions: Dietary Supplement: Vitamin C;   Dietary Supplement: Vitamin E;   Dietary Supplement: Saline (for Vitamin C);   Drug: Placebo (for Vitamin E)
Outcome Measures: The incidence of coagulation abnormalities, total blood product transfusions and the incidence of organ injury and ventilator-associated pneumonia.;   Protocol violations, 28- and 60-day mortality, ventilator-free days and duration of ICU and hospital stay.
5 Recruiting Phase 3 Safety and Efficacy Study of ART-123 in Subjects With Severe Sepsis and Coagulopathy
Conditions: Severe Sepsis;   Coagulopathy
Interventions: Drug: ART-123;   Drug: Placebo
Outcome Measures: Primary Efficacy Outcome Measure;   Primary Safety Outcome Measure;   Secondary Efficacy Outcome Measure;   Secondary Safety Outcome Measure
6 Recruiting Registry for Vascular Anomalies Associated With Coagulopathy
Conditions: Multifocal Lymphangioendotheliomatosis With Thrombocytopenia;   Cutaneovisceral Angiomatosis With Thrombocytopenia;   Vascular Anomaly With Thrombocytopenia;   Hemangiomas
Intervention: Other: no intervention
Outcome Measure: Number of patients with genetic mutations, copy number variations and/or expression analysis
7 Unknown  Evaluating the Use of Thromboelastography to Diagnose Coagulopathy After Traumatic Brain Injury
Conditions: Traumatic Brain Injury;   Coagulation Disorder
Intervention:
Outcome Measure:
8 Recruiting Fibrinogen as an Alternative to FFP in Aortic Surgery.
Condition: Coagulopathy in Patients Having Thoraco-Abdominal Aneurysm Repair
Interventions: Biological: Fibrinogen concentrate;   Biological: Fresh Frozen Plasma
Outcome Measures: Pattern of coagulation disturbance in the conventional treatment (FFP) and fibrinogen concentrate groups.;   Proportion of patients in the fibrinogen group in whom FFP transfusion is required during surgery.;   Units of FFP transfused - during surgery and up to 24 hours after surgery.;   Units of platelets and allogeneic red cells transfused - during surgery and up to 24 hours after surgery.;   Blood loss.
9 Recruiting Accuracy of a Portable International Normalized Ratio Monitor in Elderly Patients
Conditions: Blood Coagulation Disorders;   Blood Coagulation Disorder With Prolonged Bleeding Time;   Blood Coagulation Disorder With Prolonged Coagulation Time
Interventions: Device: INR capillary measurement with INRatio 2 device;   Other: antiphospholipid antibodies and lupus anticoagulant
Outcome Measures: INR by capillary method and INR by veinous punction;   Difference between International normalized ratio (INR) measured in a veinous blood punction and with a capillary method on the same patient and correlated to the level of phospholipid antibodies and lupus anti coagulant
10 Unknown  The Assessment of Tranexamic Acid in Women With Menorrhagia Who Have Bleeding Disorders
Condition: Menorrhagia
Intervention: Drug: tranexamic acid
Outcome Measures: Minimal effective dose of tranexamic acid;   Quality of Life Assessment
11 Recruiting The Genetics and Functional Basis of Inherited Platelet, White Blood Cell, Red Blood Cell, and Blood Clotting Disorders.
Condition: Glanzmann Thrombasthenia
Intervention:
Outcome Measure:
12 Recruiting Evaluation of Hemostasis in Bleeding and Thrombotic Disorders
Conditions: Hereditary Bleeding Disorder;   Thrombotic Disorder
Intervention:
Outcome Measure: Assess primary and secondary hemostasis in individuals with bleeding and clotting disorders
13 Unknown  Evaluation of Menses in Congenital Bleeding Disorders
Conditions: Von Willebrand Disease;   Congenital Coagulation Factors Deficiency;   Haemophilia Carriers
Intervention:
Outcome Measures: Quantitative determination of menstrual blood losses;   kinetic definition of menses;   Influence of treatment on menstrual blood losses;   treatment schedule evaluation
14 Recruiting Chronology of Occult and Gross Coagulopathy in Burn Patients
Condition: Thermal Burns
Intervention:
Outcome Measure:
15 Not yet recruiting Safety and Efficacy Study Comparing Pad-gauze With Anti-fibrinolytic Agent Hemostopan™) to a Regular Pad-gauze
Conditions: Bleeding;   Coagulopathy
Intervention: Device: pad-gauze with tranexamic acid (Hemostopan™)
Outcome Measure: Time to hemostasis
16 Recruiting Efficacy and Safety of Ledipasvir/Sofosbuvir Fixed-Dose Combination and Sofosbuvir + Ribavirin for Subjects With Chronic Hepatitis C Virus (HCV) and Inherited Bleeding Disorders
Condition: Chronic HCV Infection
Interventions: Drug: LDV/SOF;   Drug: Sofosbuvir;   Drug: Ribavirin
Outcome Measures: Proportion of participants with sustained virologic response 12 weeks after discontinuation of therapy (SVR12);   Incidence of adverse events leading to permanent discontinuation of study drug(s);   Proportion of participants with sustained virologic response (SVR) at 4 weeks after discontinuation of therapy (SVR4);   Proportion of participants with HCV RNA < LLOQ on treatment;   HCV RNA change from baseline;   Proportion of participants with virologic failure;   For HIV-1/HCV co-infected participants, the proportion of subjects that maintain HIV-1 RNA < 50 copies/mL while on HCV treatment;   For HIV-1/HCV co-infected participants, change from baseline of serum creatinine at the end of treatment;   For HIV-1/HCV co-infected participants, change from baseline of serum creatinine at posttreatment Week 12
17 Not yet recruiting Control of Major Bleeding After Trauma Study
Conditions: Trauma;   Hemorrhagic Shock
Interventions: Biological: Type AB plasma;   Drug: Crystalloid fluid (standard of care for resuscitation)
Outcome Measures: 28 day mortality;   Composite outcome of 28-day in-hospital mortality and postinjury multiple organ failure (MOF) incidence;   Admission Coagulopathy;   Admission clot strength;   Admission acidosis
18 Not yet recruiting Post-Marketing Requirement to Evaluate the Safety of Octaplas™ Versus Plasma in Patients Undergoing Orthotopic Liver Transplantation With Special Emphasis on Hyperfibrinolysis.
Conditions: Coagulopathy;   Endstage Liver Disease
Interventions: Biological: Octaplas™;   Biological: Plasma
Outcome Measures: To assess the incidence of hyperfibinolysis in patients undergoing OLT receiving octaplas™ versus regular plasma (e.g., fresh frozen plasma (FFP) and other FDA and American Association of Blood Banks (AABB) approved plasma products).;   The safety of octaplas™ in comparison to plasma will be assessed by monitoring the occurrence of adverse drug reactions (i.e., transfusion reactions).
19 Recruiting Point-of-Care Testing in Coagulopathic Patients Undergoing Cardiac Surgery - a Multicenter Study
Condition: Coagulopathy During Cardiac Surgery
Interventions: Device: Conventional laboratory testing (Central laboratory);   Device: POC testing
Outcome Measures: packed red blood cell concentrate (PRBC) transfusion rate;   Transfusion rate of Fresh Frozen Plasma;   Postoperative Blood loss;   Duration of mechanical ventilation;   Horovitz - indices;   Incidence of acute renal failure;   Duration of hospitalisation;   rethoracotomies;   Thromboembolic or allergic adverse events;   Ventilator - associated pneumonia;   Postoperative Sepsis;   Transfusion rate of platelet concentrates;   Age of each platelet concentrate;   Amount of infused PCC;   Amount of infused rVIIa;   Amount of infused fibrinogen concentrate
20 Unknown  Socialization of Adult Men With Congenital Hemophilia A or B
Conditions: Hemophilia A;   Hemophilia B
Intervention:
Outcome Measures: Health related quality of life, description of support and networks.;   Quality of life and description of role of SSO in health care of their PWCBD partner